f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Post-Approval PMA Cohorts Study (PACS)

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number /
Requirement Number
P070004 / PAS001
Date Original Protocol Accepted 03/09/2012
Date Current Protocol Accepted 05/29/2012
Study Name Post-Approval PMA Cohorts Study (PACS)
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives The Post-approval PMA Cohorts Study (PACS) will continue to follow subjects from premarket cohorts for 10 years in order to assess the long-term clinical performance of the approved device. The PACS data are to be collected via annual physician follow-up evaluations and all patients in the study will have MRI at years 6, 8, and 10.
Study Population Women who received Sientra' silicone breast implants and were enrolled in the premarket Core Study and reconstruction cohorts of the Continued Access Study. The data obtained at baseline on each subject will be used as the control data for physical status, cancer history and status, rheumatologic history and status, medical history and status, and CTD history and status.
Sample Size A total of 1,788 subjects have been enrolled in Sientras PACS at 33 sites throughout the United States.
Key Study Endpoints The safety endpoints include local complications, implant rupture, connective tissue diseases (CTDs), CTD signs and symptoms, lactation complications, cancer and suicide. Effectiveness will be assessed based on quality of life (QOL) assessments and subject satisfaction.
Follow-up Visits and Length of Follow-up 10 years
Interim or Final Data Summary
Actual Number of Patients Enrolled 1,788
Primary augmentation: 1,116
Revision-augmentation: 363
Primary reconstruction: 225
Revision-reconstruction: 84
Number of subjects completed 10-year visit: 1,030
Primary Augmentation: 688 (66.8%)
Revision Augmentation: 192 (18.6%)
Primary Reconstruction: 118 (11.5%)
Revision Reconstruction: 32 (3.1%)
Actual Number of Sites Enrolled 61
Patient Follow-up Rate At year 10, the overall follow-up rate for the PACS Study was 65%. Follow-up calculations were
based on the following formula: [(“Seen” (Number of Patients Completed Visit) /”Expected”
(Theoretically due – discontinued due to deaths & explants)].
The follow-up rates from year 1 to 10 for primary augmentation are 92%, 84%, 81%, 80%, 78%,
73%, 68%, 60%, 66%, and 67%, respectfully. For revision augmentation the rates are 89%, 85%,
80%, 80%, 76%, 73%, 67%, 57%, 65%, 62%, respectfully
Final Safety Findings Deaths
There were 37 known deaths in the PACS study (10 primary augmentation, 4 revisionaugmentation,
15 primary reconstruction, and 9 revision-reconstruction subjects), which is
about 2% of the population. Most are due to cancers (breast, lung, or other cancers) or other
comorbidities, 9 were “unknown”; 7 are from the reconstruction or revision-reconstruction
cohorts, which may be related to either a recurrence or metastasis of their breast cancer.
There was one “reported possible suicide” in the primary augmentation cohort.
Local Complications
Besides Baker Grade II capsular contracture, a “mild” event, the most common complication in
the primary augmentation, revision-augmentation and primary reconstruction cohorts was
Baker Grade III/IV capsular contracture (12.9%, 13.7% and 15.8%, respectively). In the revisionreconstruction
cohort, besides Baker Grade II capsular contracture, the most common
complication was asymmetry (16.9%), followed by Baker Grade III/IV capsular contracture
Implant Rupture
The 10-year risk of rupture for the MRI cohort ranged between 6.8% to 16.5% and for the non-
MRI cohort between 3.5% and 6.6%. The overall risk of rupture at 10 years is 7.9%.
Connective Tissue Diseases (CTD) signs and symptoms
The frequency of each CTD Sign/Symptom stratified by Visit & Age Group are within 5% for the
primary augmentation cohort (max=4.6%) at year 10, and within 10% for the other cohorts
(max=8.3% Revision Reconstruction, max=6.0% Primary Reconstruction, 0.0% Revision
Lactation Complications/Pregnancy Difficulties
The incidences of post-operative pregnancy difficulties were 1.7%, 1.7%, 0.9% and 0.0%. The
incidences of post-operative lactation difficulties were 11.5%, 10.6%, 0.0% and 0.0% in the
primary augmentation, revision-augmentation, primary reconstruction and revisionreconstruction
The Kaplan Meier risk for breast cancer is 0.6%, 1.6%, 2.9%, and 3.2% for the primary
augmentation cohort, the revision-augmentation cohort, the primary reconstruction cohort,
and the revision-reconstruction cohort, occurring anywhere from one to ten years after
Reasons for Reoperation
In the primary-augmentation cohort, the most common reasons for reoperation were capsular
contracture (24.7%), style/size change (20.6%) and ptosis (10.7%). In the revision-augmentation
cohort, the most common reasons remain the same, with style/size change and capsular contracture (17.4% and 16.3%, respectively). In the primary reconstruction cohort, the most
common reasons were style/size change (20.2%) and asymmetry (16.1%). In the revisionreconstruction
cohort, the most common reasons remain the same with asymmetry (23.6%),
capsular contracture (21.8%) and style/size change (16.4%).
Reasons for Explantation/Removal
In the primary augmentation cohort, the most common reasons for explantation were
style/size change (49.1%) and capsular contracture (18.7%). In the revision-augmentation
cohort, the most common reasons were style/size change (43.8%) and capsular contracture
(11.1%). In the primary reconstruction cohort, the most common reasons were style/size
change (36.0%) and asymmetry (16.2%). In the revision-reconstruction cohort, the most
common reasons were style/size change (16.4%), asymmetry (23.6%), and capsular contracture
Risk Factor Regression Analysis
For all four cohorts, Years of Implantation is associated with increased risk (p value <0.001) for
reoperation and explantation with or without replacement, and for Baker III/IV Capsular
Contracture, statistically significant. Device Surface and Placement were significant for capsular
contracture in primary augmentation, Device Surface was also significant for revision
reconstruction, and Participant’s Age was a risk factor for the revision augmentation cohort. In
Final Effect Findings In terms of patient satisfaction at 10 years, overall more than 80% patients feel more feminine
and more attractive, and more than 74% feel better.
The Mean Cup Change (and standard deviation) was 1.6 +/- 7 and circumference increased
about 1-inch post-implant, 35.4 +/- 2.4 vs. 34.2 +/- 2.2. Paired t-test showed both statistically
significant improvements in terms of bra cup size and circumference.
There were no statistically significant changes in the SF-36 Subscale scores compared to the
general female population by the 10-year visit across all four cohorts.
The mean Rosenberg Self-Esteem scale scores and changes were within one point of each other
across all four cohorts, ranging from 25.7 +/- 4.55 to 26.4 +/- 2.91. Specifically, a score of 26.0 +/-
4.34 was observed in the primary augmentation cohort, 25.9 +- 3.95 in the revision
augmentation cohort, 25.7 +/- 4.55 in the primary reconstruction cohort, and 26.4 +/- 2.91 in the
revision reconstruction cohort.
Study Strengths & Weaknesses The PACS study assessed the continued follow-up of premarket cohorts. The participants were
followed annually for 10 years to assess the long-term clinical performance of the device with acceptable follow-up rates.
The PACS study is limited by its single arm design, i.e. only silicone is used across the four
indication cohorts. In addition, the smaller number of reconstruction and revisionreconstruction
cohort also limits the generalization of its results. Readers should be cautious in
interpreting the data and in making generalizations about the target population because each
of the four cohorts mentioned have a different patient profile, and with that, different levels of
Recommendations for Labeling Changes Labeling update is recommended to reflect the long-term safety and effectiveness results

Post-Approval PMA Cohorts Study (PACS) Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 09/07/2012 09/07/2012 On Time
one year report 03/09/2013 03/12/2013 Overdue/Received
two year report 03/09/2014 03/07/2014 On Time
three year report 03/09/2015 03/10/2015 Overdue/Received
four year report 03/08/2016 03/07/2016 On Time
five year report 03/08/2017 03/03/2017 On Time
Final Report 03/09/2018 03/08/2018 On Time

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources